menu
    • menu
    [{"orgOrder":0,"company":"CervoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EIP Pharma Announces Positive Phase 2 Results for Neflamapimod in Mild-to-Moderate Dementia with Lewy bodies (DLB)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Neflamapimod","moa":"Mapk\/p38 alpha","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"CervoMed","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"CervoMed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/ Not Applicable"},{"orgOrder":0,"company":"CervoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EIP Pharma Announces Presentation of Positive Clinical Trial Results with Neflamapimod at the 13th CTAD Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Neflamapimod","moa":"Mapk\/p38 alpha","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"CervoMed","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"CervoMed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/ Not Applicable"},{"orgOrder":0,"company":"CervoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EIP Pharma Publishes Translational Data of Preclinical and Phase 2a Results for Neflamapimod in Dementia with Lewy Bodies: Nature Communications","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Neflamapimod","moa":"p38 alpha kinase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"CervoMed","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CervoMed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/ Not Applicable"},{"orgOrder":0,"company":"CervoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Presentation of MRI Data at Clinical Trials and Alzheimer's Disease (CTAD) Conference Demonstrates Potential of Neflamapimod to Positively Impact the Cholinergic Degenerative Process in Early Alzheimer's Disease (AD)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Neflamapimod","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"CervoMed","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CervoMed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/ Not Applicable"},{"orgOrder":0,"company":"CervoMed","sponsor":"CervoMed","pharmaFlowCategory":"D","amount":"$19.0 million","upfrontCash":"Undisclosed","newsHeadline":"EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Merger","leadProduct":"Neflamapimod","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"CervoMed","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"","sponsorNew":"CervoMed \/ EIP Pharma","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/ EIP Pharma"},{"orgOrder":0,"company":"CervoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EIP Pharma Announces First Patient Dosed in RewinD-LB Phase 2b Clinical Trial Evaluating Neflamapimod in Dementia with Lewy Bodies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Neflamapimod","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"CervoMed","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CervoMed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/ Not Applicable"},{"orgOrder":0,"company":"CervoMed","sponsor":"EIP Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CervoMed Announces Completion of Merger with EIP Pharma","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Merger","leadProduct":"Neflamapimod","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"CervoMed","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CervoMed \/ EIP Pharma","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/ EIP Pharma"},{"orgOrder":0,"company":"CervoMed","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$149.4 million","upfrontCash":"$50.0 million","newsHeadline":"CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Private Placement","leadProduct":"Neflamapimod","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"CervoMed","amount2":0.14999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.14999999999999999,"dosageForm":"Capsule","sponsorNew":"CervoMed \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/ RA Capital Management"},{"orgOrder":0,"company":"CervoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CervoMed Completes Enrollment in Phase 2b Trial of Neflamapimod for Dementia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Neflamapimod","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"CervoMed","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CervoMed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Neflamapimod

    Menu

    Neflamapimod

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CervoMed

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            CervoMed

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Neflamapimod

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CervoMed Completes Enrollment in Phase 2b Trial of Neflamapimod for Dementia

                            Details : VX-745 (neflamapimod), an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha. It is being evaluated for the treatment of dementia with lewy bodies.

                            Brand Name : VX-745

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 11, 2024

                            Lead Product(s) : Neflamapimod

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CervoMed

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            CervoMed

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Neflamapimod

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : RA Capital Management

                            Deal Size : $149.4 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

                            Details : The Company intends to use the net proceeds to fund research and development of its clinical-stage product candidate, VX-745 (neflamapimod), an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha.

                            Brand Name : VX-745

                            Molecule Type : Small molecule

                            Upfront Cash : $50.0 million

                            March 28, 2024

                            Lead Product(s) : Neflamapimod

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : RA Capital Management

                            Deal Size : $149.4 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            CervoMed

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            CervoMed

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Neflamapimod

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : EIP Pharma

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            CervoMed Announces Completion of Merger with EIP Pharma

                            Details : The Combined company will pursue late-stage clinical development of oral VX-745 (neflamapimod), a small molecule brain penetrant that inhibits p38MAP kinase alpha (p38a), for the treatment of dementia with Lewy bodies.

                            Brand Name : VX-745

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 16, 2023

                            Lead Product(s) : Neflamapimod

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : EIP Pharma

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            CervoMed

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            CervoMed

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Neflamapimod

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            EIP Pharma Announces First Patient Dosed in RewinD-LB Phase 2b Clinical Trial Evaluating Neflamapimod in Demen...

                            Details : VX-745 (neflamapimod) is an investigational drug that is an orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha, which is investigated for the treatment of dementia with lewy bodies.

                            Brand Name : VX-745

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 14, 2023

                            Lead Product(s) : Neflamapimod

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            CervoMed

                            Country arrow
                            Luxepack
                            Not Confirmed

                            CervoMed

                            Country arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Neflamapimod

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : CervoMed

                            Deal Size : $19.0 million

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treat...

                            Details : The Combined company will pursue late-stage clinical development of oral neflamapimod, a small molecule brain penetrant that inhibits p38MAP kinase alpha (p38a), for the treatment of dementia with Lewy bodies.

                            Brand Name : VX-745

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 30, 2023

                            Lead Product(s) : Neflamapimod

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : CervoMed

                            Deal Size : $19.0 million

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            CervoMed

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            CervoMed

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Neflamapimod

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Presentation of MRI Data at Clinical Trials and Alzheimer's Disease (CTAD) Conference Demonstrates Potential o...

                            Details : VX-745 (neflamapimod) is an investigational oral, brain-penetrating small molecule drug. The combined pre-clinical and clinical data are consistent with neflamapimod treating the underlying disease process and having the potential to be the first disease...

                            Brand Name : VX-745

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 02, 2022

                            Lead Product(s) : Neflamapimod

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            CervoMed

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            CervoMed

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Neflamapimod

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            EIP Pharma Publishes Translational Data of Preclinical and Phase 2a Results for Neflamapimod in Dementia with ...

                            Details : Neflamapimod (VX-745) is an investigational oral, brain-penetrating small molecule drug that inhibits the intra-cellular enzyme p38MAP kinase alpha (p38α which is expressed in neurons under conditions of stress and disease.

                            Brand Name : VX-745

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 21, 2022

                            Lead Product(s) : Neflamapimod

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            CervoMed

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            CervoMed

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Neflamapimod

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            EIP Pharma Announces Presentation of Positive Clinical Trial Results with Neflamapimod at the 13th CTAD Meetin...

                            Details : Results of AscenD-LB Phase 2 clinical study demonstrate proof-of-concept for neflamapimod as a treatment for dementia with Lewy bodies (DLB).

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 09, 2020

                            Lead Product(s) : Neflamapimod

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            CervoMed

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            CervoMed

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Neflamapimod

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            EIP Pharma Announces Positive Phase 2 Results for Neflamapimod in Mild-to-Moderate Dementia with Lewy bodies (...

                            Details : Patients receiving neflamapimod three times daily demonstrated significant improvement on the NTB compared to those who received either placebo or neflamapimod twice daily.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 06, 2020

                            Lead Product(s) : Neflamapimod

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth